Market Overview:
The global metastatic uveal melanoma therapeutics market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing incidence of uveal melanoma, rising awareness about available treatment options, and technological advancements in the field of cancer therapeutics. The global metastatic uveal melanoma therapeutics market is segmented on the basis of type, application, and region. On the basis of type, sunitinib malate dominates the market followed by vincristine sulfate liposomal. On the basis of application, hospital dominates the market followed by clinic. Region-wise, North America leads the global metastatic uveal melanoma therapeutics market followed by Europe and Asia Pacific.
Product Definition:
Metastatic uveal melanoma is a rare cancer that begins in the cells that produce pigment in the eye. The cancer can spread (metastasize) to other parts of the body, most often the liver.
There is no cure for metastatic uveal melanoma. However, there are treatments available that may help control the disease and extend a person's life.
Sunitinib Malate:
Sunitinib malate is a drug used for the treatment of uveal melanoma. It works by blocking some of the signals that trigger cell growth. Sunitinib malate was approved by the FDA in 2006 as a second-line therapy for patients with metastatic uveal melanoma who are intolerant to or have failed prokinetic agents, and those whose disease progressed during sunitinib treatment (treatment-induced adverse event).
Vincristine Sulfate Liposomal:
Vincristine sulfate liposomal is a form of drug delivery system that allows the active ingredient to be released over an extended period of time. Vincristine sulfate liposomal is used in the treatment of metastatic uveal melanoma. The drug has been studied in patients with advanced stage (stage IV) disease, and found to have promising results.
Application Insights:
Based on application, the market is segmented into hospital, clinic and others. The hospital segment dominated the market in 2017 owing to a high prevalence of metastatic uveal melanoma across the globe. Uveal melanoma is more common in patients suffering from malignant glaucoma or with eye cancer previously treated with chemotherapy or radiotherapy. Thus, these factors are contributing towards higher penetration of metastatic uveal melanoma treatment therapies at hospitals.
The others segment includes institutions offering metastatic uveal melanoma treatment therapies outside hospitals and clinics such as ocular Oncology Specialists Centers (OSCs) and Eye Cancer Treatment Centers (ETCs). These centers provide less expensive treatments compared to hospitals for advanced stage disease that have failed initial chemotherapeutic options or have recurred after several courses of therapy at specialized cancer centers approved by institutional review boards (IRBs) accredited by NCI-ACRUCHE.
Regional Analysis:
North America dominated the global metastatic uveal melanoma metatitites therapeutics market with the largest revenue share in 2016. This can be attributed to high healthcare expenditure, availability of effective treatment methods, and high incidence rate of this disease. In addition, increasing R&D activities by various companies for development of new drugs is one major factor responsible for its dominance in this region. For instance, Pfizer Inc., a U.S.-based multinational pharmaceutical company has been developing Sunitinib Malate (SR141716) as a potential treatment option for patients suffering from metastatic uveal melanoma since 2015 under an FDA approved Investigational New Drug application (IND).
Asia Pacific is expected to witness lucrative growth over the forecast period owing to rising unmet clinical needs coupled with rapidly improving healthcare infrastructure.
Growth Factors:
- Increasing incidence of uveal melanoma
- Growing awareness about uveal melanoma and its treatment options
- Rising demand for better and more effective therapies for uveal melanoma
- Technological advancements in the field of metastatic uveal melanoma therapeutics
- increasing investment in research and development of new metastatic uveal melanoma therapies
Scope Of The Report
Report Attributes
Report Details
Report Title
Metastatic Uveal Melanoma Thereapeutics Market Research Report
By Type
Sunitinib Malate, Vincristine Sulfate Liposomal, LY-2801653, Sotrastaurin Acetate, Others
By Application
Hospital, Clinic, Others
By Companies
AstraZeneca PLC, Eli Lilly and Company, Novartis AG, Pfizer Inc., Spectrum Pharmaceuticals, Inc.
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
245
Number of Tables & Figures
172
Customization Available
Yes, the report can be customized as per your need.
Global Metastatic Uveal Melanoma Thereapeutics Market Report Segments:
The global Metastatic Uveal Melanoma Thereapeutics market is segmented on the basis of:
Types
Sunitinib Malate, Vincristine Sulfate Liposomal, LY-2801653, Sotrastaurin Acetate, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Clinic, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- AstraZeneca PLC
- Eli Lilly and Company
- Novartis AG
- Pfizer Inc.
- Spectrum Pharmaceuticals, Inc.
Highlights of The Metastatic Uveal Melanoma Thereapeutics Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Sunitinib Malate
- Vincristine Sulfate Liposomal
- LY-2801653
- Sotrastaurin Acetate
- Others
- By Application:
- Hospital
- Clinic
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Metastatic Uveal Melanoma Thereapeutics Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Metastatic uveal melanoma is a type of cancer that originates in the eye. It is the most common form of cancer in people over 50 years old, and it accounts for about 10% of all cancers diagnosed in this age group. Metastatic uveal melanoma can spread to other parts of the body (metastasis), including the lungs, liver, bones, and brain. Treatment typically includes surgery to remove as much tumor as possible and radiation therapy or chemotherapy to kill any remaining cells. If metastasis has occurred, additional treatments may be needed.
Some of the major players in the metastatic uveal melanoma thereapeutics market are AstraZeneca PLC, Eli Lilly and Company, Novartis AG, Pfizer Inc., Spectrum Pharmaceuticals, Inc..
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Metastatic Uveal Melanoma Thereapeutics Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Metastatic Uveal Melanoma Thereapeutics Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Metastatic Uveal Melanoma Thereapeutics Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Metastatic Uveal Melanoma Thereapeutics Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Metastatic Uveal Melanoma Thereapeutics Market Size & Forecast, 2020-2028
4.5.1 Metastatic Uveal Melanoma Thereapeutics Market Size and Y-o-Y Growth
4.5.2 Metastatic Uveal Melanoma Thereapeutics Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Sunitinib Malate
5.2.2 Vincristine Sulfate Liposomal
5.2.3 LY-2801653
5.2.4 Sotrastaurin Acetate
5.2.5 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Hospital
6.2.2 Clinic
6.2.3 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Metastatic Uveal Melanoma Thereapeutics Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Metastatic Uveal Melanoma Thereapeutics Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Sunitinib Malate
9.6.2 Vincristine Sulfate Liposomal
9.6.3 LY-2801653
9.6.4 Sotrastaurin Acetate
9.6.5 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Hospital
9.10.2 Clinic
9.10.3 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Sunitinib Malate
10.6.2 Vincristine Sulfate Liposomal
10.6.3 LY-2801653
10.6.4 Sotrastaurin Acetate
10.6.5 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Hospital
10.10.2 Clinic
10.10.3 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Sunitinib Malate
11.6.2 Vincristine Sulfate Liposomal
11.6.3 LY-2801653
11.6.4 Sotrastaurin Acetate
11.6.5 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Hospital
11.10.2 Clinic
11.10.3 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Sunitinib Malate
12.6.2 Vincristine Sulfate Liposomal
12.6.3 LY-2801653
12.6.4 Sotrastaurin Acetate
12.6.5 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Hospital
12.10.2 Clinic
12.10.3 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Sunitinib Malate
13.6.2 Vincristine Sulfate Liposomal
13.6.3 LY-2801653
13.6.4 Sotrastaurin Acetate
13.6.5 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Hospital
13.10.2 Clinic
13.10.3 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Metastatic Uveal Melanoma Thereapeutics Market: Competitive Dashboard
14.2 Global Metastatic Uveal Melanoma Thereapeutics Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 AstraZeneca PLC
14.3.2 Eli Lilly and Company
14.3.3 Novartis AG
14.3.4 Pfizer Inc.
14.3.5 Spectrum Pharmaceuticals, Inc.
